Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 16.21B, Moderna(MRNA) trades at $41.50. The stock has a price-to-earnings ratio of -4.88.
On 2026-01-16, Moderna(MRNA) stock traded between a low of $39.56 and a high of $42.30. Shares are currently priced at $41.50, which is +4.9% above the low and -1.9% below the high.
Moderna(MRNA) shares are trading with a volume of 9.23M, against a daily average of 13.48M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $45.40 and a 52-week low of $22.28.
MRNA News
The European Patent Office appeals board has revoked one of Arbutus Biopharma’s (ABUS) patents, which is likely to affect its case against Moderna (MRNA) in Swi...
In early 2026, Moderna raised its 2025 revenue forecast to about US$1.9 billion, outlined meaningful operating expense cuts, and reiterated a path toward cash b...
Massachusetts-based Moderna Inc. (NASDAQ:MRNA) is seeing fresh momentum in recent weeks, with the stock off to a flying start in 2026. The company that rose to...
Analyst ratings
70%
of 27 ratingsMore MRNA News
Moderna (MRNA) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Moderna’s latest Phase 4 study, titled “A Phase 4, Randomiz...
Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which reg...
Moderna (MRNA) is back in focus after its J.P. Morgan Healthcare Conference update, where management lifted the 2025 revenue forecast to about US$1.9b, outlined...
Moderna rallies after projecting better-than-expected 2025 sales Moderna rallied more than 15% on Tuesday after saying on Monday that its COVID-19 business did...
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Tuesday. Shares of Moderna Inc (NASDAQ:MRNA) rose sharply during Tuesday's sessio...
Moderna (MRNA) is up 12.9%, or $4.37 to $38.21. Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time, market-moving br...
William Blair analyst Myles Minter has reiterated their neutral stance on MRNA stock, giving a Hold rating yesterday. Claim 70% Off TipRanks Premium Unlock hedg...